SynthesisEuropean journal of clinical pharmacology2023

Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.

Jalal Arabloo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.